262 related articles for article (PubMed ID: 3260130)
1. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
2. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
5. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
[TBL] [Abstract][Full Text] [Related]
6. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
[TBL] [Abstract][Full Text] [Related]
7. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
Haranaka K; Sakurai A; Satomi N
J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
10. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa.
Matsumoto T; Tateda K; Miyazaki S; Furuya N; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
Cytokine; 1999 May; 11(5):366-72. PubMed ID: 10328876
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
Hauser GJ; McIntosh JK; Travis WD; Rosenberg SA
Cancer Res; 1990 Jun; 50(12):3503-8. PubMed ID: 2340500
[TBL] [Abstract][Full Text] [Related]
17. Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins.
Andus T; Geiger T; Hirano T; Kishimoto T; Heinrich PC
Eur J Immunol; 1988 May; 18(5):739-46. PubMed ID: 2454192
[TBL] [Abstract][Full Text] [Related]
18. IL-4 and TNF-alpha-mediated proliferation of the human megakaryocytic line M-O7E is regulated by induced autocrine production of GM-CSF.
Wadhwa M; Dilger P; Meager A; Walker B; Gaines-Das R; Thorpe R
Cytokine; 1996 Dec; 8(12):900-9. PubMed ID: 9050748
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
20. [Effect of 131I-labeled recombinant human tumor necrosis factor-alpha on the nude mice bearing human hepatoma].
Long YH; Li YC; Mi YX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):787-92. PubMed ID: 19950584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
